Terig Hughes
Director of Finance/CFO chez VOLITIONRX LIMITED
Fortune : 241 400 $ au 31/03/2024
Profil
Terig Hughes is currently working as a Director at Singapore Volition Pte Ltd., Volition Global Services SRL, and as the Chief Financial Officer & Treasurer at VolitionRX Ltd.
In the past, he worked as the Managing Director-India & Southeast Asia at RELX Group Plc from 2014 to 2017, as the Vice President-Finance at Elsevier, Inc. from 2003 to 2006, and as the Chief Financial Officer at AUM Biosciences Pte Ltd.
from 2018 to 2020.
Mr. Hughes completed his undergraduate and graduate degrees from De Montfort University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VOLITIONRX LIMITED
0,39% | 24/01/2024 | 318 890 ( 0,39% ) | 241 400 $ | 31/03/2024 |
Postes actifs de Terig Hughes
| Sociétés | Poste | Début |
|---|---|---|
| VOLITIONRX LIMITED | Director of Finance/CFO | 01/02/2021 |
Singapore Volition Pte Ltd.
 Singapore Volition Pte Ltd. Hospital/Nursing ManagementHealth Services Part of VolitionRX Ltd., Singapore Volition Pte Ltd. provides diagnostic services for cancer patients. Singapore Volition was acquired by Standard Capital Corp. on October 07, 2011 for $0.07 million. | Director/Board Member | 01/09/2021 |
| Volition Global Services SRL | Director/Board Member | 01/09/2021 |
Anciens postes connus de Terig Hughes
| Sociétés | Poste | Fin |
|---|---|---|
AUM Biosciences Pte Ltd.
 AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The private company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | Director of Finance/CFO | 01/01/2020 |
RELX Group Plc
 RELX Group Plc Packaged SoftwareTechnology Services RELX Group Plc engages in the provision of information and analytics for professional and business customers. It operates in four major segments such as scientific, technical and medical, risk and business analytics, legal and exhibitions. The company was founded on September 11, 1992 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/01/2017 |
Elsevier, Inc.
 Elsevier, Inc. Publishing: Books/MagazinesConsumer Services Elsevier, Inc. publishes journals, online materials, and books. It offers Scopus, ScienceDirect, Mendeley, Evolve, Knovel, Reaxys and ClinicalKey. The company is headquartered in Newton, MA. | Corporate Officer/Principal | 01/01/2006 |
Formation de Terig Hughes
| De Montfort University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VOLITIONRX LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Elsevier, Inc.
Elsevier, Inc. Publishing: Books/MagazinesConsumer Services Elsevier, Inc. publishes journals, online materials, and books. It offers Scopus, ScienceDirect, Mendeley, Evolve, Knovel, Reaxys and ClinicalKey. The company is headquartered in Newton, MA. | Consumer Services |
RELX Group Plc
RELX Group Plc Packaged SoftwareTechnology Services RELX Group Plc engages in the provision of information and analytics for professional and business customers. It operates in four major segments such as scientific, technical and medical, risk and business analytics, legal and exhibitions. The company was founded on September 11, 1992 and is headquartered in London, the United Kingdom. | Technology Services |
Singapore Volition Pte Ltd.
Singapore Volition Pte Ltd. Hospital/Nursing ManagementHealth Services Part of VolitionRX Ltd., Singapore Volition Pte Ltd. provides diagnostic services for cancer patients. Singapore Volition was acquired by Standard Capital Corp. on October 07, 2011 for $0.07 million. | Health Services |
AUM Biosciences Pte Ltd.
AUM Biosciences Pte Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AUM Biosciences Ltd., AUM Biosciences Pte Ltd. is a clinical-stage biotech company based in Singapore, Singapore. The Singaporean company focuses on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. AUM Biosciences has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and contributing significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3 billion. AUM Biosciences is advancing a broad portfolio of precision oncology therapeutics, including AUM001, AUM601, and AUM302, which have entered clinical trials and received orphan drug designation from the FDA for the treatment of various cancers. The private company was founded by Harish Dave and is currently led by CEO Vishal Doshi. | Commercial Services |
| Volition Global Services SRL |
